EMAIL THIS PAGE TO A FRIEND

Human molecular genetics

CNS expression of murine fragile X protein (FMRP) as a function of CGG-repeat size.


PMID 24463622

Abstract

Large expansions of a CGG-repeat element (>200 repeats; full mutation) in the fragile X mental retardation 1 (FMR1) gene cause fragile X syndrome (FXS), the leading single-gene form of intellectual disability and of autism spectrum disorder. Smaller expansions (55-200 CGG repeats; premutation) result in the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS). Whereas FXS is caused by gene silencing and insufficient FMR1 protein (FMRP), FXTAS is thought to be caused by 'toxicity' of expanded-CGG-repeat mRNA. However, as FMRP expression levels decrease with increasing CGG-repeat length, lowered protein may contribute to premutation-associated clinical involvement. To address this issue, we measured brain Fmr1 mRNA and FMRP levels as a function of CGG-repeat length in a congenic (CGG-repeat knock-in) mouse model using 57 wild-type and 97 expanded-CGG-repeat mice carrying up to ~250 CGG repeats. While Fmr1 message levels increased with repeat length, FMRP levels trended downward over the same range, subject to significant inter-subject variation. Human comparisons of protein levels in the frontal cortex of 7 normal and 17 FXTAS individuals revealed that the mild FMRP decrease in mice mirrored the more limited data for FMRP expression in the human samples. In addition, FMRP expression levels varied in a subset of mice across the cerebellum, frontal cortex, and hippocampus, as well as at different ages. These results provide a foundation for understanding both the CGG-repeat-dependence of FMRP expression and for interpreting clinical phenotypes in premutation carriers in terms of the balance between elevated mRNA and lowered FMRP expression levels.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

MAB2160
Anti-Fragile X Mental Retardation Protein Antibody, clone 1C3, Anti-Fragile X Mental Retardation Protein Antibody, clone 1C3 detects level of Fragile X Mental Retardation Protein & has been published & validated for use in ELISA, IC, IH, IH(P) & WB.
AB2302
Anti-GAPDH Antibody, Anti-GAPDH Antibody detects level of GAPDH & has been published & validated for use in WB.
MAB374
Anti-Glyceraldehyde-3-Phosphate Dehydrogenase Antibody, clone 6C5, Anti-Glyceraldehyde-3-Phosphate Dehydrogenase Antibody, clone 6C5 is a well published and extensively characterized monoclonal antibody. This purified mAb detects Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) & has been published & validated for use in ELISA, IP, IC, IF, IH & WB.
GW22763 Anti-GAPDH antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB3500247
Anti-GAPDH antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB1405848
Anti-GAPDH antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
WH0002332M1
Monoclonal Anti-FMR1 antibody produced in mouse, clone 2D4, purified immunoglobulin, buffered aqueous solution
SAB1403834
Monoclonal Anti-FMR1 antibody produced in mouse, clone 3E11, purified immunoglobulin, buffered aqueous solution
SAB4100418
Monoclonal Anti-FMR1 antibody produced in mouse, clone FMR1-B317, culture supernatant
WH0002597M1
Monoclonal Anti-GAPDH antibody produced in mouse, clone 3C2, purified immunoglobulin, buffered aqueous solution